Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Allakos Inc (NQ: ALLK )

103.63 UNCHANGED
Streaming Delayed Price Updated: 4:03 PM EST, Nov 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 103.63
Bid (Size) 7.350 (1)
Ask (Size) 199,999.98 (1)
Prev. Close 103.63
Today's Range 103.63 - 103.63
52wk Range 41.60 - 139.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
From GlobeNewswire News Releases

Performance

YTD
+11.08%
+11.08%
1 Month
+13.80%
+13.80%
3 Month
+18.71%
+18.71%
6 Month
+42.86%
+42.86%
1 Year
+14.19%
+14.19%

More News

Read More
Allakos Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
From GlobeNewswire News Releases
Allakos Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
From GlobeNewswire News Releases
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
From GlobeNewswire News Releases
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Me
From GlobeNewswire News Releases
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Implied LABU Analyst Target Price: $102
Tags ETFs
From ETF Channel
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.